Selvita – integrated drug discovery partner

News Archive

Selvita Group and Polfa Warszawa announce commencement of a collaboration

Selvita Group and Polfa Warszawa announce commencement of a collaboration concerning the analytical work necessary to prepare the registration dossier for a medicinal product.

The scope of the project, commissioned to Selvita Group, includes development, validation and transfer of analytical methods for characterizing substances resulting from the degradation product of a complex formulation. Due to the intricacy of the project, studies will require the use of non-standard, highly specialized analytical techniques.

"We are delighted that a company with such a rich history, experience and reputation as Polfa Warszawa decided to use our services - said Dr. Milosz Gruca, Director of Research and Development, a Board Member of BioCentrum which belongs to the Selvita Group. We hope that our cooperation will expand in the future, so that Polfa Warszawa will be able to concentrate on its core activities related to the production of drugs, and Selvita Group will be able to support it in the field of research and development."

"We hope that this will be the beginning of a long collaboration, which will allow us for prompt preparation of registration dossiers. This way we will be able to deliver new products to the market faster, for the benefit of patients." - said Ms. Karolina Pokorowska, Spokesperson for Polfa Warszawa SA

The project covered by the agreement is implemented for the preparation by Polfa Warszawa of a medicinal product registration. All tests performed by the Selvita Group will be carried out in accordance with the requirements of the European Medicines Agency. Results of the work will be prepared in the CTD format, allowing Polfa Warszawa to directly use them in the documentation submitted to the Office of Registration of Medicinal Products, Medical Devices and Biocidal Products .

Selvita Group is an innovative Polish company providing research and development services and IT solutions. We deliver comprehensive solutions for pharmaceutical and research companies targeted at lowering the cost of bringing products to market. The group also includes BioCentrum, which has been audited and qualified by the General Pharmaceutical Inspectorate in the field of therapeutical substance manufacturing for the physicochemical analyses of the substances and their certification. BioCentrum’s offer includes services in chemical analysis (eg. development, validation and transfer of methods of API analysis, stability testing, dissolution profiles), protein chemistry (incl. analysis of amino acid composition and sequencing), in vitro preclinical studies (ADME) crystallography, and enzyme production.

Polfa Warszawa SA is one of the largest and most known Polish pharmaceutical companies. Polfa Warszawa SA manufactures 140 formulations, which are exported to over thirty countries. Polfa Warszawa is a leading manufacturer of hospital drugs and cardiac preparations. Upper respiratory track clearing medicines, drugs produced by Polfa represent nearly half the domestic market. Currently the company is at the selection stage of an investor who will finalize the ongoing privatization process.

Selvita participates in the 10th World Congress on Inflammation

Place: 25-29th June 2011, Palais des Congres, Paris, France

The World Congress on Inflammation is a biennal congress organized by the International Association of Inflammation Societies, which is a non-profit making organization which aims to promote international co-operation among inflammation scientists as well as providing a communication network between inflammation societies throughout the world.

To contact Selvita's delegate at this event please write an email to : This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Selvita presents at the BioEquity Europe 2011

Place: Paris, 23^rd-24^th May, 2011, Paris Marriott Rive Gauche, Paris, France

Selvita will present during the upcoming BioEquity Europe conference in Paris.

BioEquity Europe has become a magnet for financial and pharmaceutical company dealmakers, and is the premier venue for biopharma companies looking to attract capital and expand their business development efforts. The 2011 conference is set to offer an unparalleled showcase of investment opportunities at a critical time for the life sciences.

We cordially invite you to our presentation at this event.

To arrange a meeting with Selvita's delegate at this conference, please contact: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Selvita sponsors and presents at the 2nd Annual Congress Discovery Partnerships

Place: 25th-27th January 2011, Dorint Hotel Sanssouci, Berlin-Potsdam, Germany

The 2nd Annual Congress Discovery Partnerships is organised under the theme of "From tactical to strategic partnerships" and aims to help establish efficient collaboration & outsourcing strategies for all participants.

This event creates opportunity to discuss different outsourcing and partnering strategies and learn some best practice scenarios from industry leaders.
Key areas of discussion will include:
- Comparison of cutting-edge business and risk-sharing models for drug discovery
- Identification of best practices for planning and managing discovery partnerships.

We cordially invite you to our presentation "Poland - attractive European pre-clinical outsourcing destination for all pharmaceutical and biotech companies", given by Mr. Piotr Prelich, Selvita's VP of Marketing and Sales.
Presentation will take place on Wednesday, 26th January 2011, at 10:50 am.

More about 2nd Annual Congress Discovery Partnerships

Selvita participates in BioFinance & BioInnovate 2011

Place: London, 17 June 2011, London Stock Exchange, London, UK

The 2011 BIA BioFinance and BioInnovate Europe conference is focused on life sciences as an enabling technology, bringing benefits to patients, economies and investors. With a range of top-level speakers from global pharma and bioscience companies of all sizes, venture capital, the public sector, CROs and networks, the latest issues in finance and innovation will be discussed and debated.

If you'd like to contact Selvita's delegate at this conference, please contact us at: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it , or call at: +48 12 297 47 00.

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>